US Broker Ratings

AbbVie Inc. (ABBV): Investor Outlook and Potential 11.84% Upside with Strong Analyst Support

AbbVie Inc. (NYSE: ABBV), a behemoth in the healthcare sector, continues to capture investor attention with its robust market presence and promising developments in its drug pipeline. With a market..

Agilent Technologies, Inc. (A) Stock Analysis: A Compelling 25.63% Potential Upside Amid Robust Revenue Growth

Agilent Technologies, Inc. (NYSE: A), a leading player in the healthcare sector, particularly in the diagnostics and research industry, offers a significant opportunity for investors with its projected upside potential..

Waters Corporation (WAT) Stock Analysis: Navigating a 4.51% Upside in the Diagnostics & Research Sector

Waters Corporation (NYSE: WAT) stands as a formidable player in the healthcare sector, specifically within the diagnostics and research industry. With a market capitalization of $23.36 billion, this U.S.-based company..

BioNTech SE (BNTX) Stock Analysis: Evaluating the 21.77% Potential Upside Amidst Clinical Innovations

BioNTech SE (NASDAQ: BNTX), a trailblazer in the biotechnology sector, has captured investor attention with its promising pipeline of immunotherapies aimed at treating various forms of cancer and infectious diseases...

Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: Navigating a 10.15% Potential Upside Amidst Healthcare Innovation

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands out in the biotechnology industry as a formidable player in the healthcare sector. With a market capitalization of $79.87 billion, this U.S.-based company continues..

Labcorp Holdings Inc. (LH) Stock Analysis: Unpacking the 12.52% Potential Upside

Labcorp Holdings Inc. (NYSE: LH), a key player in the healthcare sector, particularly within the Diagnostics & Research industry, has been on investors’ radar due to its solid market presence..

Edwards Lifesciences (EW) Stock Analysis: Navigating a 15.96% Upside in the Medical Devices Sector

Edwards Lifesciences Corporation (NYSE: EW), a prominent player in the healthcare sector specializing in medical devices, has garnered significant attention from investors, not least due to its potential upside of..

Gilead Sciences, Inc. (GILD) Stock Analysis: What Investors Need to Know About Its Strong ROE and Dividend Yield

Gilead Sciences, Inc. (NASDAQ: GILD) stands out in the healthcare sector as a formidable force in drug manufacturing. With a market capitalization of $168.66 billion, this biopharmaceutical giant has solidified..

Novo Nordisk A/S (NVO) Stock Analysis: Impressive ROE and Strategic Collaborations in Focus

Novo Nordisk A/S (NYSE: NVO), a titan in the healthcare sector, continues to capture the attention of investors with its commanding market presence and impressive financial metrics. As a leading..

The Cigna Group (CI) Investor Outlook: Analyzing Its 17% Potential Upside and Strong Buy Ratings

For investors navigating the complex waters of the healthcare sector, The Cigna Group (NYSE: CI) presents a compelling opportunity. With a market capitalization of $74.58 billion, this industry stalwart is..

CVS Health Corporation (CVS): Investor Outlook Highlights 14.40% Potential Upside

CVS Health Corporation (NYSE: CVS), a titan in the healthcare sector, stands as a compelling investment opportunity with a market capitalization of $105.38 billion. As a key player in the..

Boston Scientific Corporation (BSX) Stock Analysis: A 34% Potential Upside Amidst Strong Growth

Boston Scientific Corporation (NYSE: BSX), a leading player in the healthcare sector, is making waves in the medical devices industry with a market capitalization of $137.19 billion. As healthcare continues..

Haleon plc (HLN) Stock Analysis: A Promising 13.03% Potential Upside in the Healthcare Sector

For investors seeking exposure in the healthcare sector, Haleon plc (HLN) presents an intriguing opportunity with a potential upside of 13.03%, according to analyst targets. Haleon operates in the specialty..

Sanofi (SNY) Investor Outlook: A Healthcare Giant with a 23% Upside Potential

Sanofi (SNY), a leading player in the global healthcare sector, offers a compelling investment opportunity for individual investors with a keen focus on the drug manufacturing industry. Headquartered in Paris,..

Eli Lilly & Co. (LLY) Stock Analysis: A $954 Billion Pharma Giant with Robust Revenue Growth and Promising Upside

Eli Lilly and Company (NYSE: LLY), a stalwart in the healthcare sector, has consistently demonstrated its prowess in the pharmaceutical industry. With a market capitalization nearing $954 billion, Eli Lilly..

Vertex Pharmaceuticals (VRTX) Stock Analysis: A Biotech Leader with 8% Potential Upside

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), a titan in the biotechnology sector, has long been a beacon for innovation, primarily focusing on the treatment of cystic fibrosis (CF). With a market..

Danaher Corporation (DHR) Stock Analysis: Exploring a Potential 11.93% Upside with Strong Buy Ratings

Danaher Corporation (NYSE: DHR), a titan within the healthcare sector, has consistently demonstrated its prowess in the diagnostics and research industry. With a robust market capitalization of $168.28 billion, Danaher..

AstraZeneca PLC (AZN) Stock Analysis: Promising Growth with a 6.56% Potential Upside

AstraZeneca PLC (AZN), a heavyweight in the healthcare sector, continues to capture investor attention with its robust pipeline and strategic collaborations. As a leading biopharmaceutical company headquartered in Cambridge, UK,..

UnitedHealth Group (UNH) Stock Analysis: Navigating Healthcare’s Robust Performer with a 10.53% Upside Potential

UnitedHealth Group Incorporated (NYSE: UNH) is a titan in the healthcare sector, commanding a market capitalization of $322.71 billion. As a diversified healthcare company, it operates through four main segments:..

Emergent BioSolutions Inc. (EBS) Stock Analysis: Is the 11.66% Upside Worth the Risk?

Emergent BioSolutions Inc. (NYSE: EBS), the Maryland-based life sciences company, is drawing attention from investors with its potential upside of 11.66%. Known for its extensive portfolio of preparedness and response..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds